Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Renal Cell 23Sarcoma 18Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Liposarcoma 5Leiomyosarcoma 5Hemangiosarcoma 5Sarcoma, Synovial 4Neurofibrosarcoma 4Lung Neoplasms 4Kidney Neoplasms 4Histiocytoma, Malignant Fibrous 4Urinary Bladder Neoplasms 3Recurrence 3Prostatic Neoplasms 3Glioblastoma 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Gliosarcoma 2Fibrosarcoma 2Dermatofibrosarcoma 2Clear-cell metastatic renal cell carcinoma 2

Interventions

Temozolomide 2Everolimus 2Capecitabine 2Bevacizumab 2regorafenib 1pazopanib 1motesanib diphosphate 1batifiban 1Sorafenib 1Panobinostat 1Oxaliplatin 1Octreotide 1Leucovorin 1Fluorouracil 1Fentanyl 1Doxorubicin 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Insulinoma × pazopanib × Clear all
NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
52 enrolled 11 charts
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡